Plain English Summary
Background and study aims
Asthma is a common long-term health condition caused by inflammation of the small tubes (bronchi) that carry air in and out of the lungs. Symptoms vary in severity and include coughing, wheezing, a tightness in the chest and feeling breathless. It occurs when the sufferer comes in contact with something that irritates their lungs – a trigger - causing their airways to narrow and an increase in the production of phlegm in their airways. Common triggers include house dust mites, animal fur, pollen, cigarette smoke, exercise and viral infections (such as a cold). The focus of asthma treatment is on medication, usually with inhalers, and the response to poorly controlled asthma (PCA) is often to increase medication. However, asthma affects people in many ways, including effects on emotions, concentration and self-management behaviour. Having attacks of breathlessness can be frightening, and some may become anxious or depressed. Significant anxiety is six times as common in people with asthma, particularly when control is poor. Those with anxiety are more likely to have asthma attacks, have more frequent attacks, worse symptoms and have a lower quality of life. Anxiety is often not talked about with doctors, so can be untreated. The Department of Health has recently made studies of psychological treatments in asthma a research priority. Notably, there is a relatively poor association between the symptoms of asthma (e.g. physiological measurement of lung function) and how bad patients themselves consider their asthma to be. However, there is a stronger relationship between how anxious patients feel and how severe they think their asthma is. Currently, there is a lot of research examining thought-processing biases in anxiety (for example, people with anxiety more quickly notice negative stimuli in the environment). However, the corresponding research has not been conducted in asthma. This area of research will therefore benefit greatly from research that reconciles findings from both anxiety and asthma.
Who can participate?
Adults diagnosed with asthma
What does the study involve?
Participants take a bronchial challenge test (or methacholine challenge), which is a medical test that helps is diagnosing asthma. It involves the patient breathing in methacholine, a drug that causes the airways to narrow (bronchoconstriction). They will be asked complete some short and simple computer tasks and questionnaires before and after the methacholine challenge. These computer tasks and questionnaires will be used to understand participants’ thought processes, and how they are affected by asthma.
What are the possible benefits and risks of participating?
Participants do not benefit directly from taking part in this study. However, the results may increase researchers understanding of asthma and lead to improved diagnosis and treatment in the future. They may also benefit from gaining a more thorough understanding of their condition and how it affects them. Possible side effects include a feeling of being tight chested or coughing during the methacholine challenge, however this is a likely to be very mild.
Where is the study run from?
University Hospital Southampton (UK)
When is the study starting and how long is it expected to run for?
April 2016 to April 2017
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
1. Dr Ben Ainsworth (scientific)
2. Mrs Megan Liddiard (public)
Dr Ben Ainsworth
School of Psychology
University of Southampton
Mrs Megan Liddiard
School of Psychology
Investigating maladaptive cognitive biases in patients with asthma using a bronchial hyperreactivity challenge.
The trialists predict an association between subjective symptoms of asthma and anxiety-related thought processes. Specifically, they hypothesize that increased anxiety will be related to increased perception of breathlessness/asthma severity (regardless of actual measures of physiological lung function).
City Road and Hampstead Research Ethics Committee, 13/01/2016, ref: 15/LO/1898
Within-subjects design using standardised cognitive and behavioural measures
Primary study design
Secondary study design
Non randomised study
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Participants will complete some baseline measures of lung function and psychological measures. They will then complete the key outcome measures (computer tasks, and anxiety-related questionnaires) DURING a bronchial challenge.
The bronchial challenge is known as a methacholine challenge. Patients will be asked to inhale a drug called Methacholine to assess how reactive to ‘twitch’ the muscles in the airways are. They start with a very low inhaled amount, and measure whether patients’ airways tighten at all by repeating the blowing test (spirometry). If they don’t, or do so very little, a slightly higher dose inhalation will be given and the spirometry will be repeated. This will continue for up to 7 inhalations, stopping if patients start to feel bad or when the blowing test has reduced to 4/5 of the original level. Inhaling this agent may make patients wheeze or cough a bit. At the end of the test we will ask patients to do the computer tasks, and then we will give you some salbutamol (reliever inhaler medication) to reverse the effects of methacholine.
They will complete the same measures after the bronchial challenge, and results will be compared.
Primary outcome measures
1. Attentional functioning, measured using the computerized Attention network test
2. Attention biases towards threatening stimuli, measured using a dot-probe task
3. Severity of anxiety, measured using the spielberger state-trait anxiety inventory
Measured during vs. after methacholine challenge
Secondary outcome measures
1. Mindfulness and attention questionnaires, measured using the MAAS and ACS
2. Asthma control/quality of life, measured using the ACQ and AQLQ
Measured at baseline
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Adult (over 18 years)
2. Confirmed diagnosis of asthma. Asthma severity will be clinically diagnosed according to BTS guidelines from Step 1 [mild intermittent asthma] to Step 4 [persistent poor control], have an FEV1 of 60% or more in order to undergo methacholine challenge
Target number of participants
Participant exclusion criteria
1. Patients under 18 years of age
2. Comorbid psychological disorders other than anxiety/depression (measured using the MINI 3. neuropsychiatric interview questionnaire)
4. Currently participating in an active asthma intervention study
5. Have had acute exacerbation of asthma (needing a course of oral steroid of increased dose of maintenance steroid) with 28 days of the first intervention study
Asthma severity is characterised according to BTS guidelines as Step 5 (continuous or frequent use of oral steroids)
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
University Hospital Southampton
University of Southampton
National Institute for Health Research
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Publications will be submitted to peer-reviewed internation journals and presented at conferences
Intention to publish date
Participant level data
To be made available at a later date
Results - basic reporting